Drug intelligence / Profile preview

mk-1708

Development stage: Phase 1
Lead developer: Merck
Modality: Small Molecules
Administration: Oral

Overview

MK-1708 is an investigational therapeutic agent developed by Merck Sharp & Dohme. It is currently being studied as a potential treatment for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). MK-1708 is classified as an antidementia drug, but its precise mechanism of action has not been defined publicly. As of early 2025, it remains a new molecular entity in phase 1 clinical trials, with studies focusing on its safety, tolerability, and pharmacokinetics in both healthy elderly participants and adults. No orphan drug status has been granted to date[2][3][1].

Beyond the preview

Go deeper on mk-1708.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mk-1708.

Explore the full profile